Adma Biologics (ADMA) Receivables - Net (2012 - 2025)

Adma Biologics (ADMA) has 14 years of Receivables - Net data on file, last reported at $158.4 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Net rose 216.86% year-over-year to $158.4 million; the trailing twelve-month figure through Dec 2025 stood at $158.4 million (up 216.86% YoY), and the FY2025 full-year result was $158.4 million, up 216.86% from the prior year.
• Receivables - Net for Q4 2025 stood at $158.4 million, up from $137.7 million in the prior quarter.
• Across five years, Receivables - Net topped out at $158.4 million in Q4 2025 and bottomed at $15.4 million in Q1 2021.
• The 5-year median for Receivables - Net is $29.3 million (2021), against an average of $48.8 million.
• The widest annual swing landed in 2022, when Receivables - Net tumbled 45.74%; it then surged 264.38% in 2025.
• A 5-year view of Receivables - Net shows it stood at $28.6 million in 2021, then sank by 45.74% to $15.5 million in 2022, then soared by 76.85% to $27.4 million in 2023, then jumped by 82.34% to $50.0 million in 2024, then jumped by 216.86% to $158.4 million in 2025.
• The last three Receivables - Net figures came in at $158.4 million (Q4 2025), $137.7 million (Q3 2025), and $109.7 million (Q2 2025), per Business Quant data.

Peer Comparison